Dr Humaira Kalam
Principle Investigator
MBBS, PLAB ( UK), MRCOG (Part 1)
Medical Officer Ash Shefa Hospital, Chittagong, Bangladesh
Peer Reviewed Articles
- Kalam H, Osti B, Ria SG, Bristy MM, Kamal RB, Anan M, Islam MT, Al Mobarak S. Antimicrobial resistance in Bangladesh: a looming public health crisis. IJS Global Health. 2026 May 1;9(3):e00627.
- Khan A, Khan A, Rai KD, Saeed A, Kumar H, Sangtiani AK, Fatima T, Alam MT, Rajput F, Chawla S, Shah HH. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Comprehensive Review of Types, Pathophysiology, and Treatment Approaches. Brain and Behavior. 2026 May;16(5):e71458.
- Masood RZ, Ali M, Manzoor SF, Sajid EU, Kalam H. Virtual reality as a transformative tool in pain management. Annals of Medicine and Surgery. 2025 Sep 1;87(9):5368-9.
- Ahmad M, Kalam H. Tafasitamab (MOR208) in relapsed or refractory follicular lymphoma: a promising frontier in targeted immunotherapy. Annals of Medicine and Surgery. 2025 Dec 1;87(12):7866-7.
- Nawaz J, Rathi D, Kalam H. The digital health revolution: transforming healthcare delivery through telemedicine in the post-pandemic era. Annals of Medicine and Surgery. 2025 Nov 1;87(11):6926-7.
- Hujjat SF, Zahra SH, Abbas T, Kalam H. Tonmya (cyclobenzaprine hydrochloride sublingual tablets): first FDA-approved therapy for fibromyalgia in over 15 years. Annals of Medicine and Surgery. 2025 Dec 1;87(12):7868-9.
